Second, mediators should learn their own weaknesses to reduce their susceptibility to engagement. The first step is the use of systems analysis to sensitize the mediator to how conflict manifests itself. However, approaching conflict too closely distorts the information needed to manage the conflict although it is difficult for the lawyer-mediator to maintain the appropriate distance and avoid engagement, but it is possible. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.The mediator needs reliable information from clients, who provide this information through the conflict process. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Such statements include those relating to our presentation at Retina Forum, Euretina and AAopt. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. This press release contains forward-looking statements. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and autosomal dominant retinitis pigmentosa. Sepofarsen is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and received fast-track designation and rare pediatric disease designation from the FDA as well as access to the PRIME scheme by the EMA. Sepofarsen is designed to enable normal splicing, resulting in restoration of normal (wild type) CEP290 mRNA and subsequent production of functional CEP290 protein. The p.Cys998X mutation leads to aberrant splicing of the mRNA and non-functional CEP290 protein. Sepofarsen (QR-110) is being evaluated in the pivotal Phase 2/3 Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber congenital amaurosis 10 due to the p.Cys998X mutation (also known as the c.2991+1655A>G mutation) in the CEP290 gene. A live questions and answers session will be held on Friday October 9, 2020, 7:30-9:30 PM EDT. Maldonado, MD, Assistant Professor of Ophthalmology at Shriners UK Advances Eye Care at the University of Kentuckyĭate: The poster presentation will be available on the AAOpt Virtual Platform starting October 7, 2020. Presentation title: Survey of Early Genetic Diagnosis of Inherited Retinal Diseases (IRDs) and Patient Referrals: The important role of Optometrists in the early management of blinding genetic diseases Leroy, MD, PhD, principal investigator of the ProQR Phase 1/2 clinical trial of sepofarsen and Chairman and Head of the Department of Ophthalmology at the Center for Medical Genetics at the Ghent University Presentation title: RNA antisense oligonucleotide sepofarsen in Leber Congenital Amaurosis type 10 (LCA10): disease severity and patient response based on genotype Russell, MD, principal investigator of the ProQR Phase 1/2 clinical trial of sepofarsen Professor and Director of Vitreoretinal Diseases and Surgery Service, Department of Ophthalmology and Visual Sciences, University of Iowaĭate: The poster presentation will be available on the Euretina Virtual Congress portal starting October 2, 2020. Presentation title: Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10) Presenter: Aniz Girach, MD, Chief Medical Officer of ProQR
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |